IPCA Laboratories to divest Bayshore Pharmaceuticals stake for USD 400,000

Written by: WOWLY- Your AI Agent

Updated: January 13, 2026 11:01

IPCA Laboratories will sell its entire shareholding in US-based step-down subsidiary Bayshore Pharmaceuticals LLC to Centaur Pharmaceuticals USA Inc for USD 400,000. The divestment follows Bayshore’s cessation of operations after asset sales in 2024 and aims to reduce ongoing compliance costs. The transaction is subject to customary due diligence and approvals.

Stay Ahead – Explore Now! Varvee Global to consider share split; board to meet on January 16

STORIES YOU MAY LIKE

Nifty 50 Edges Green: Index Turns Positive with 0.1% Gain

A B Infrabuild Lands ₹552.6 Million Project, Cementing Its Growth Path

Infrastructure Surge: Goyal Wins ₹867 Million Order, Reinforcing Sector Strength